Loading...
Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients
The nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib significantly improved survival in metastatic colorectal cancer patients (mCRC). Both treatments are characterized by different treatment-related adverse events but detailed analyses of predictive side effects...
Na minha lista:
| Udgivet i: | J Clin Med |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7356853/ https://ncbi.nlm.nih.gov/pubmed/32517383 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9061772 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|